Superworth

Nephros EV/EBIT NEPH

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2023.

Today, Nov 2, 2026
18.6×
3-year median
30.6×
Against its 3-year history
7th
percentile: 0 is its lowest day, 100 its highest
3-year range
15.8× to 63.4×
Peer median
7.7×

Nephros' EV/EBIT is 18.6× as of Nov 2, 2026.

That is below its 3-year median of 30.6×, lower than on 93% of days in the last 3 years.

Over that time it ranged from 15.8× in Sep 2023 to 63.4× in Jun 2025.

The median for 6 medical instruments and supplies stocks of a similar size is 7.7×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far18.6×18.1×61.6×
202532.7×24.4×63.4×
2024n/m a value too high to mean anything
202319.2×15.8×51.7×

Against its peers

Companies in Medical - Instruments & Supplies nearest Nephros' size, closest first, today.

CompanyEV/EBIT
NEPHNephros18.6×
APTAlpha Pro Tech8.1×
KEQUKewaunee Scientific7.3×
PDEXPro DEX14.8×
UTMDUtah Medical Products4.8×
INFUInfuSystem22.2×
EMBCEmbecta6.6×
Peer median7.7×

Where Nephros ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Nephros

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.